ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12 2024 - 7:30AM
Arecor Therapeutics plc(“Arecor”
or the “Company”)
ARECOR AND TRx BIOSCIENCES ESTABLISH
RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED
BIOAVAILABILITY
- Companies to combine
proprietary technologies to formulate an oral semaglutide (GLP-1
receptor agonist) product with enhanced
bioavailability
- Collaboration focused on
overcoming the challenges of oral peptide delivery using a novel
lipid technology to provide a more convenient treatment option for
patients with diabetes and obesity
- Potential to expand
collaboration across multiple oral peptide products and combination
therapies in growing global market
Cambridge, UK, 12 March 2024:
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group
advancing today’s therapies to enable healthier lives, and TRx
Biosciences Limited, a drug development company applying novel
lipid technology to the oral delivery of challenging molecules,
today announced a research collaboration for the formulation
development of an oral glucagon-like peptide-1 (GLP-1) receptor
agonist product.
GLP-1 receptor agonists are a class of
therapeutic peptides used to treat type 2 diabetes and obesity, in
a global market predicted to reach $80-$100+ billion by 20301. Oral
delivery of this class of drug is extremely challenging owing to
the proteolytic nature of the digestive system which significantly
reduces bioavailability. Injection remains the most common delivery
form for therapeutic peptide drugs, limiting adoption, compliance
and usage among patients, who would prefer a simpler, more
practical oral therapy.
The only GLP-1 receptor agonist currently
available to patients in pill form – Novo Nordisk’s semaglutide
(Rybelsus®) – has oral bioavailability of less than 1%2. Using TRx
Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s
formulation platform, Arestat™, the companies intend to jointly
develop an oral GLP-1 receptor agonist product with enhanced
physicochemical properties that can achieve higher oral
bioavailability and stability.
Sarah Howell, Chief Executive Officer of
Arecor, said: “As the global market for GLP-1 receptor
agonists grows and their use increases, significant challenges
remain in their oral delivery. With current treatment options
mostly limited to injectable therapies, many patients in need are
unable to benefit from these highly effective treatments. Arecor
has an excellent track record developing difficult-to-achieve
product profiles by deploying our Arestat™ technology to develop
unique formulations specifically designed to overcome
patient-focussed challenges. Alongside TRx Biosciences and its
expertise in targeted oral drug delivery, we have an opportunity to
develop an enhanced oral GLP-1 receptor agonist product. In
addition, if the initial research collaboration is successful, we
would hope to leverage the technology to deliver other high value
peptides via patient- preferred oral delivery formats. I look
forward to providing further updates in due course.”
Dr Robin Bannister, Chief Executive
Officer of TRx Biosciences, said: “The effective oral
delivery of peptides remains a ‘holy grail’, meaning patients that
require the convenience of oral treatment can’t access the benefits
of new peptide therapies. By combining TRx’s LipiCore™ technology
with Arecor’s proven peptide expertise and Arestat™ platform, we
create the opportunity to access novel oral uptake channels and
protect peptides from damage in the gastrointestinal tract to solve
this fundamental challenge. Semaglutide, given its immense
potential in the treatment of diabetes and obesity, is a highly
attractive starting point. Success with semaglutide may offer a
path to multiple oral peptide products with enhanced absorption and
efficacy.”
The collaboration provides scope for expansion,
following the initial oral GLP-1 receptor agonist programme, to
develop further oral peptide products. These include additional
peptides and combination approaches which may be key in the
treatment of obesity-related health conditions, as well as peptide
products targeting multiple therapeutic areas.
-ENDS-
References
1. Anti-Obesity Drug Sales Could
Hit $80 Billion by 2030 Bloomberg Intelligence
The increase in appetite for
obesity drugs J.P. Morgan Global
Research Novo Nordisk faces
several 'overlooked' trends including competition for Wegovy, warns
investment bank Proactive 2. Clinical
Pharmacokinetics of Oral Semaglutide: Analyses of Data from
Clinical Pharmacology Trials. Clin Pharmacokinet. 2021
Oct;60(10):1335-1348. doi: 10.1007/s40262-021-01025-x. Epub 2021
May 10
For more information, please contact:
Arecor Therapeutics plc |
www.arecor.com |
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060Email: info@arecor.com |
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060Email: info@arecor.com |
|
|
Panmure Gordon (UK) Limited (NOMAD and
Broker) |
|
Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden
(Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
|
|
WG Partners LLP (Financial Advisor) |
|
Nigel Barnes, Satheesh NadarajahDavid Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
ICR Consilium |
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com |
|
|
Notes to Editors
About Arecor Arecor
Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary technology platform, Arestat™,
we are developing an internal portfolio of proprietary products in
diabetes and other indications, as well as working with leading
pharmaceutical and biotechnology companies to deliver therapeutic
products. The Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our website,
www.arecor.com
American Resources (NASDAQ:AREC)
Historical Stock Chart
From Jul 2024 to Aug 2024
American Resources (NASDAQ:AREC)
Historical Stock Chart
From Aug 2023 to Aug 2024